February 8, 2021
Infection and MRNA-1273 Vaccine Antibodies Neutralize SARS-CoV-2 UK Variant
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): vaccines, variants
[Pre-print, not peer-reviewed] A study using a live virus neutralization assay to compare potency of neutralization between people who had been infected with SARS-CoV-2 or had received the Moderna COVID-19 vaccine against a panel of SARS-CoV-2 variants showed that antibodies in sera from both groups were effective at neutralizing the B.1.1.7 variant. Serum neutralization titers were measured using a live-virus Focus Reduction Neutralization Test (FRNT) assay and compared between the B.1.1.7 variant and a non-variant strain among acutely infected COVID-19 patients (R2 = 0.7971), convalescent individuals (R2 = 0.8092), and vaccinated individuals (R2 = 0.7639).
Edara et al. (Feb 5, 2021). Infection and MRNA-1273 Vaccine Antibodies Neutralize SARS-CoV-2 UK Variant. Pre-print downloaded Feb 8 from https://doi.org/10.1101/2021.02.02.21250799